secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2025-11-24T23:59:59+00:00
Accession:  0001193125-25-292057
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio presents GBM trial data: mPFS 13.0 mo vs 6.6 SOC; mOS not reached at 16.4+ mo
--------------------------------------------------------------------------------

- Phase 1 INB-200 and Phase 2 INB-400 data presented at SNO 2025 for newly diagnosed glioblastoma.
- 14 patients received repeated DeltEx DRI gamma-delta T cells; mPFS 13.0 months vs 6.6 for SOC (n=10).
- Median OS not yet reached for DRI patients at 16.4+ months as of Oct 31, 2025; SOC mOS 11.0 months.
- 17 patients treated across both trials; 10 additional SOC-only patients monitored for comparison.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525292057/0001193125-25-292057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525292057/d11812d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-292057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer